ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced data from a Phase 1b trial of ...
Beech Tree is the holding company owning directly and indirectly the stake in Ipsen shares of Mr. Beaufour. Alasol Foundation is a public interest foundation created by Mr. Beaufour to promote ...
Sapu003 is a novel intravenous nanoparticle formulation of everolimus engineered using Sapu Nano’s proprietary Deciparticle ™ technology. It is designed to overcome the poor bioavailability, ...
Next Steps Based on these data, 80 mg QD oral enozertinib has been selected as the dose for potential Phase 3 development. Enrollment and follow-up continues in 1L EGFR PACC patients with the next ...
J.P. Morgan, TD Cowen and Piper Sandler are acting as joint book-running managers. LifeSci Capital is acting as a lead manager of the offering. H.C. Wainwright & Co. is acting as a manager of the ...
The POLARIS-1 trial is a global, multicenter, randomized controlled, open-label Phase III study designed to evaluate the efficacy and safety of olverembatinib in combination with chemotherapy in newly ...
Company Presentation Details Event: Sidoti Year End Investor Conference Date: Thursday, December 11, 2025 Time: 2:30 PM ET Register to watch the virtual presentation here.
Robert Weiss has been a cornerstone of CooperCompanies success for nearly five decades, serving as CEO from 2007 until his retirement in 2018. He also served as President of CooperVision, COO, and CFO ...
The EMBOLD topline results will be presented at the American Epilepsy Society Annual Meeting at the Georgia World Congress Center, Poster Hall B2, 1.38 from 12:00-2:00 p.m. on Saturday, December 6, ...
SAN RAMON, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today financial results for its fiscal fourth quarter and full ...
TOKYO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) today announced that its subsidiary, MEDIROM MOTHER Labs Inc. (“MOTHER Labs”), which develops ...
J.P. Morgan, TD Cowen and Piper Sandler are acting as joint book-running managers of the proposed offering.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback